GlaxoSmithKline PLC April 27 released its first quarter results showing a handsome payoff for a diversification policy the pharmaceutical giant implemented three years ago. Although GSK overall sales declined 11%, strong growth in emerging markets and Japan helped offset losses from key products and bolster the net profit up by 14%.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.
Public Company Edition: OrbiMed partners Carter Neild and Matthew Rizzo spoke with Scrip about the firm’s fifth royalty and credit fund. Also, Ligand sold $400m worth of notes, BridgeBio’s oncology spinout went public via SPAC merger and raised $261m and Assembly raised $175m.
Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.
